<code id='2B13B3EB45'></code><style id='2B13B3EB45'></style>
      • <acronym id='2B13B3EB45'></acronym>
      <center id='2B13B3EB45'><center id='2B13B3EB45'><tfoot id='2B13B3EB45'></tfoot></center><abbr id='2B13B3EB45'><dir id='2B13B3EB45'><tfoot id='2B13B3EB45'></tfoot><noframes id='2B13B3EB45'>
      • <optgroup id='2B13B3EB45'><strike id='2B13B3EB45'><sup id='2B13B3EB45'></sup></strike><code id='2B13B3EB45'></code></optgroup>
        5. <b id='2B13B3EB45'><label id='2B13B3EB45'><select id='2B13B3EB45'><dt id='2B13B3EB45'><span id='2B13B3EB45'></span></dt></select></label></b><u id='2B13B3EB45'></u>
          <i id='2B13B3EB45'><strike id='2B13B3EB45'><tt id='2B13B3EB45'><pre id='2B13B3EB45'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-01 08:42:10 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：7
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Let's speed up science by embracing open access publishing
                                
                            
          Next article：  
                                      
                                          Hollywood unions extend contract negotiations for actors
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles